CD47’s long goodbye
Despite magrolimab’s latest flop, efforts to target CD47 continue.
KRAS and conjugates remain hot
The latest clinical study listings reveal KRAS-targeting projects, ADCs and others starting phase 1.
GSK’s Blenrep Dreamm remains alive
Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.
A cancer pipeline cull from AbbVie
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
AbbVie sees a world according to GARP
On a wing and a prayer AbbVie takes livmoniplimab into phase 3.
Takeda thins the cell therapy pipeline
The end of three licensed assets sees Takeda take a step back from autologous cell therapy.
Shattuck gears up for go/no go year
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
